Leveraging previous studies describing the pharmacokinetics properties of entinostat29, we also demonstrated that EVI1 protein levels markedly decrease in circulating AML blasts following 4 mg/m2 of entinostat compared to ara-C both in treated patients (Fig. 4G) or in the matched 3q26 PDLX models (Supplementary Fig. 6E). Here, RUNX1 is linked to acute myeloid leukemia.